Sermorelin was FDA-approved twice. Both approvals were withdrawn in 2009.

Why this note exists

"Sermorelin is FDA-approved" is a claim you will meet in a search result, and it is one of the harder claims in this category to grade, because the true answer changes tense. It was approved. The approval was withdrawn at the manufacturer's request. FDA later put on the record that the withdrawal had nothing to do with safety or efficacy. Every one of those sentences is true, and stacked in the wrong order they produce an impression the file does not support.

In the index generated on August 15, 2026, 66 of 112 vendors carried a sermorelin listing — 104 listings, twenty-first of 83 compounds by vendor coverage.[18] Seventy-five of those listings pass pepmg's comparability filters, and across them the median price is $7.20 per milligram, ranging from $3.60 to $15.00, a 4.2× spread.[18] Two of the 104 listings use the name GHRH anywhere in the product title; none uses the name GEREF, and none says sermorelin acetate.[18]

A note on what kind of evidence this is: every efficacy figure below is human data, carried with its design and participant count. There is no animal-data paragraph in this note, because the questions it asks — what was approved, why it left, what was measured in people — are answerable from human records alone. Where a study used a modified analogue rather than sermorelin itself, that is said in the same sentence as its result.

The record

Two applications, two indications, and the exact dates

The cleanest account of sermorelin's regulatory life is a two-page Federal Register notice from March 2013, which exists for an unrelated reason and happens to contain the whole timeline.[1] It records that the 0.5 mg and 1.0 mg vials were approved under NDA 20-443 on September 26, 1997, that the 0.05 mg ampoule was approved under NDA 19-863 on December 28, 1990, and that both applications were held by EMD Serono.[1] Drugs@FDA still lists both, both marked Discontinued, and an August 24, 2026 query of FDA's own application database returned no third application of any kind naming sermorelin acetate as an active ingredient — no generic, no new NDA, nothing.[2][3][4]

The two indications were different jobs. The 1990 product was a diagnostic: a single intravenous dose used to ask whether the pituitary can release growth hormone when told to. The 1997 product was a treatment, and its indication named the population precisely — idiopathic growth hormone deficiency in children with growth failure.[1] Neither indication describes a healthy adult.

The exit is documented letter by letter. On July 11, 2008 the holder notified FDA that the 0.05 mg ampoule was being discontinued; on December 2, 2008 it gave the same notice for the 0.5 and 1.0 mg vials and requested withdrawal of NDA 20-443; on December 12, 2008 it requested withdrawal of NDA 19-863 as well.[1] FDA announced the withdrawal of both applications in the Federal Register of May 19, 2009, effective June 18, 2009.[1] A manufacturer walking away is the entire mechanism here — there is no adverse-event finding, no efficacy failure, and no enforcement action anywhere in the record.[1]

The sentence that gets quoted, and the thirteen years that followed it

In October 2012 a private petitioner asked FDA to determine whether GEREF had been pulled for safety or efficacy reasons — a procedural question with a commercial purpose, since a generic application cannot refer to a listed drug that was withdrawn for those reasons.[1] FDA reviewed its files, evaluated the literature for postmarketing adverse events, extended the question to the diagnostic product on its own initiative, and concluded that both GEREF products "were not withdrawn from sale for reasons of safety or effectiveness."[1]

That is a real finding and it is worth stating plainly: nothing in FDA's files suggested the drug hurt people or failed. It is also, read honestly, a finding about paperwork. The notice says what the finding unlocks — abbreviated new drug applications referring to GEREF "may be approved by the Agency as long as they meet all other legal and regulatory requirements for the approval of ANDAs."[1]

So the interesting number is the one on the other side of that door. In the thirteen years since, no applicant has put a sermorelin product back on the US market; FDA's application database still shows exactly the two withdrawn NDAs.[4] The commercial reading is the same one that explains 2008: recombinant growth hormone does the pediatric job more effectively, and a 1999 review had already found that height-velocity gains on sermorelin were less than those on somatropin at the same microgram-per-kilogram dose.[6] A drug that is safe, modestly effective, and second-best has a hard time attracting a generic filing.

The approved evidence

110 children, one arm, no control group

The published efficacy evidence behind the treatment indication is a multicenter study of GHRH(1-29) in growth-hormone-deficient children, run by the Geref International Study Group and reported in 1996. Its design is the first thing to read: 110 previously untreated prepubertal children, treated for up to one year, open label, with no control group, at 30 µg/kg/day subcutaneously at bedtime; 86 of the 110 were eligible for the efficacy analysis.[5]

The results, as reported: mean height velocity rose from 4.1 ± 0.9 cm/yr at baseline to 8.0 ± 1.5 cm/yr at six months and 7.2 ± 1.3 cm/yr at twelve months; 74% of the children were considered good responders at six months; the ratio of bone-age change to height-age change was not significantly different from unity at twelve months (1.04 ± 0.58, P = 0.63), meaning the children were not simply burning through their remaining growth potential; and the authors reported no adverse biochemical or hormonal changes, no change in fasting glucose, and no excessive IGF-1 generation.[5]

The 1999 review in BioDrugs is the most careful synthesis of the whole file, and its verbs are deliberately weak. It concludes that "limited data indicate that once daily subcutaneous sermorelin 30 µg/kg bodyweight given at bedtime is effective in treating some prepubertal children with idiopathic growth hormone deficiency," that increases in height velocity were less than those seen with somatropin at the same dose, and that the effect of long-term treatment on final adult height "is yet to be determined."[6] On the diagnostic side it is more positive: a 1 µg/kg intravenous dose is "a rapid and relatively specific test," producing fewer false-positive growth hormone responses in children without deficiency than other provocative tests — with the important caveat that a normal response cannot rule out a deficiency originating in the hypothalamus.[6] Reported adverse events were transient facial flushing and injection-site pain.[6]

The adult evidence

Three studies, forty older adults, two to sixteen weeks

Nothing above is about adults, and the adult literature is the part the market is implicitly citing. It is thinner than almost anyone assumes. The three substantial administration studies in older adults all date from the 1990s and dosed forty people between them.

Participant counts and durations as reported in each paper. Doses appear here as their sources published them, with population and route attached; pepmg does not convert a published research dose into a protocol.[7][8][9]

The 1992 study is the origin of the modern claim. Ten healthy old men and nine young men were sampled at baseline; the old men then took 0.5 mg and 1 mg of GHRH(1-29) subcutaneously twice daily for 14 days each, with a 14-day gap between. Growth hormone and IGF-1 rose, but the paper is precise about where: significant increases in 24-hour GH, area under peaks, peak amplitude and IGF-1 occurred only at the high dose, after which the old men's values no longer differed significantly from the young men's.[7] Fasting glucose, urinary C-peptide, blood pressure and chemistry panels were unaffected.[7] The authors' own conclusion is a hypothesis, and it is worth quoting because thirty-four years of marketing have been built on it: short-term administration reverses age-related decreases in GH and IGF-1, "suggesting that prolonged treatment could improve age-related alterations in body composition."[7]

The 1997 San Diego study is the closest thing to a controlled test of that suggestion, and it comes with two qualifications that are usually dropped. It was single-blind, not double-blind, and it ran 4 weeks of placebo followed by 16 weeks of drug in the same people rather than randomizing two parallel groups; and the compound was [Nle27]GHRH-(1-29)-NH₂, a norleucine-substituted analogue, not sermorelin itself.[8] In 19 adults aged 55 to 71 at 10 µg/kg nightly, nocturnal GH rose in both sexes and IGF-1 and IGFBP-3 rose within two weeks — and IGF-1 then drifted back, remaining elevated for 12 weeks and "returning toward baseline by 16 weeks in both genders."[8] On the outcomes people actually buy for, the results were partial and sex-split: skin thickness increased in both sexes; lean body mass increased in men only, with no other change in body composition or bone mineral density in either sex; insulin sensitivity improved in men only; general well-being and libido improved in men only; sleep quality was unaffected in both.[8] The one adverse effect reported was transient hyperlipidemia, which resolved.[8] A companion paper on the same 19 participants reported immune-cell changes over the same window — B cells up 30% at 16 weeks, no change in T cells or natural killer cells — and is, like its sibling, a 19-person study.[10]

The 1997 Johns Hopkins study is the one that most resembles how the compound is sold, and it is the least encouraging. Eleven healthy men aged 64 to 76 with low baseline IGF-1 self-injected 2 mg nightly at home for six weeks, open-label, with no placebo group. Nocturnal GH release rose. IGF-1, IGFBP-3 and GH-binding protein did not change at all.[9] Two of six muscle-strength measures and one endurance test improved; weight, BMI, waist-to-hip ratio, DEXA measures of muscle and fat, muscle histology, glucose, insulin and lipids did not.[9] The authors' reading was mechanistic rather than promotional: single nightly doses "are less effective than multiple daily doses of GHRH in eliciting GH- and/or IGF-I-mediated effects."[9]

Put together, the honest summary is narrow and not nothing: in older adults, GHRH(1-29) and a close analogue reliably increased growth hormone release, moved IGF-1 in two studies out of three, and produced small, inconsistent, mostly male-skewed changes in body composition and strength over six to sixteen weeks. No study ran longer than five months. No study measured a clinical outcome. And the largest of them enrolled nineteen people.[7][8][9]

The confusion

Half the "GHRH" literature people cite is a different molecule

Sermorelin is GHRH(1-29) — the first 29 residues of growth hormone-releasing hormone, characterized as the shortest fragment with the parent molecule's full biological activity.[6] Tesamorelin, developed as TH9507, is a stabilized full-length GHRH(1-44) analogue, and it is a different drug with a live FDA approval and its own separate record. The two are routinely collapsed into "GHRH" in secondary write-ups, and the collapse always runs in sermorelin's favor.

The clearest example is the study most often waved at when someone claims GHRH improves cognition in aging. SMART — Somatotrophics, Memory, and Aging Research Trial — is a randomized, double-masked, parallel-group phase 2 study with 151 participants, which is an order of magnitude larger than anything in the sermorelin file.[12] Its registry record names the intervention: "TH9507 human growth hormone releasing hormone (GHRH), 1mg subcutaneous injection given daily for 20 weeks."[12] That is tesamorelin. It is not evidence about sermorelin.

The registry makes the same point structurally. A ClinicalTrials.gov intervention search for sermorelin on August 24, 2026 returned 27 studies — and not one of the 27 lists sermorelin by name in its intervention field.[11] The matches are studies of "GHRH," "growth hormone releasing hormone (GHRH) 1-44," "TH9507" and "Tesamorelin," most of them completed in the 1990s and 2000s. Of the 27, twenty-one are completed, three terminated, one withdrawn, one of unknown status — and exactly one is recruiting, a phase 2 trial of tesamorelin as an adjunct to exercise in people with HIV.[11][13]

Where it sits now

Not approved, not on FDA's safety-risk list, and named in this year's reviews

Two 2026 narrative reviews put sermorelin where it actually lives, which is a direct-to-patient market rather than a clinical one. A review in Sports Medicine covering approved and unapproved peptides marketed direct to patients lists sermorelin alongside BPC-157, CJC-1295, ipamorelin, MOTS-c, GHK-Cu and TB-500, and its general conclusion is the one that matters: many unapproved peptides show favorable outcomes in animal models, but "rigorous human safety data are scarce."[16] A review in Frontiers in Endocrinology published in June 2026 names sermorelin first among the GHRH analogues clinicians encounter in "online self-administration protocols," and explicitly stratifies this class of peptides "into evidence tiers from regulatory-grade randomized trial data to a complete absence of human studies."[17] Neither review is a trial; both are secondary sources, cited here for what they characterize rather than for any effect estimate.

On compounding, this note deliberately stops short of a legal conclusion. FDA's interim policy sorts nominated bulk substances into three categories, and describes category 2 as substances for which "FDA has identified significant safety risks relating to the use of these substances in compounding pending further evaluation."[14] FDA's page listing those substances did not name sermorelin when it was queried on August 24, 2026, although it named several other peptides that act on the same axis.[15] That absence is a fact about one FDA list on one date. Whether any particular pharmacy may lawfully compound sermorelin turns on the statutory conditions in section 503A and on state law, and pepmg makes no claim either way.[14]

The market

What 66 vendors are actually selling

The listing side of this is unusually orderly, which is its own tell: sermorelin is a settled, high-coverage staple rather than a compound anyone is making claims about. Across the 104 listings in the August 15, 2026 index, 10 mg and 5 mg vials account for 78 of them — 48 and 30 respectively — with the remainder scattered from 2 mg to 200 mg multi-vial packs.[18] Six listings are flagged as blends or combination packs, including sermorelin paired with GHRP-2 and GHRP-6; one is a nasal spray; one is listed at zero dollars, titled as a free gift.[18]

Two contrasts are worth putting next to each other, without drawing a conclusion neither side supports. The approved pediatric dose was 30 µg/kg once nightly, and the approved diagnostic dose was a single 1 µg/kg intravenous injection.[6] The vial that dominates the research market holds 10 mg.[18] Those are different products for different purposes, and pepmg makes no claim about the contents of any vendor's vial — but a reader comparing a 1990s label to a product page should know they are not looking at the same scale of thing.

Three things this note is not saying

First, it is not saying sermorelin was found unsafe. The opposite is on the record: FDA reviewed its files and the postmarketing literature and determined the withdrawal was not for reasons of safety or effectiveness, and the trials that exist reported mild, transient adverse events — flushing, injection-site pain, one episode of transient hyperlipidemia that resolved.[1][6][8]

Second, it is not saying sermorelin does nothing. It has a defined mechanism at the pituitary GHRH receptor, it was good enough at provoking growth hormone release to be approved as a diagnostic, and in every adult study cited here it raised growth hormone release.[6][7][8][9] Raising a hormone level is a pharmacodynamic result, not a clinical one, and the studies stop there.

Third, it is not saying the 1990s studies were bad studies. They were small, careful, mechanistic investigations that ended with an explicit call for longer work — "prolonged treatment could improve age-related alterations in body composition" — and no longer confirmatory trial was identified in the sources reviewed here.[7] The gap in this file is not a contradiction; it is an absence.

What the note is saying is narrower: sermorelin's FDA approvals were real, they covered a pituitary provocative test and growth failure in children, they ended on June 18, 2009 for commercial reasons, and the adult evidence a buyer is standing on is three studies from the 1990s totalling forty older adults, the longest of which ran sixteen weeks and watched IGF-1 drift back toward baseline before it stopped.[1][7][8][9]

Questions people are asking